Dr Reddy’s Laboratories to acquire generic injectable products in the US
Dr Reddy’s Laboratories has agreed to acquire a portfolio of 42 approved, non-marketed abbreviated new drug applications (ANDAs) in the US, which includes more than 30 generic injectable products, from an undisclosed seller. The generic injectable products would need technology transferred and may be launched within 1-2 years. According to IQVIA, the value of the […]